MedTrace Logo

Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma

NCT01898403 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-05-24

Study results available
· View outcomes & findings →

Summary

This clinical trial compares and contrasts lymph node mapping using indocyanine green (IC-GREEN), isosulfan blue (ISB), and TSC and Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC).

Study participants with malignant melanoma will undergo all 3 evaluations to assess the extent of the spread of the melanoma.

Conditions

  • Recurrent Melanoma

Interventions

DRUG

Indocyanine green solution

Administered peri-tumoral and intradermally

DRUG

Isosulfan blue (ISB)

Administered peri-tumoral and intradermally

DIAGNOSTIC_TEST

Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)

Sponsors & Collaborators

Principal Investigators

  • Ralph Greco · Stanford University Hospitals and Clinics

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-06-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01898403 on ClinicalTrials.gov